Immunomedics is a leader in next generation antibody-drug conjugate (ADC) technology, committed to helping transform the lives of people with hard-to-treat cancers. Our proprietary ADC binds to Trop-2-expressing cancer cells and is internalized with the subsequent release of SN-38 via hydrolysis of the linker. SN-38 interacts with topoisomerase I and prevents re-ligation of topoisomerase I-induced single strand breaks. For additional information, please visit our website, https://www.immunomedics.com/
Trodelvy: https://trodelvy.com/
Facebook: https://www.facebook.com/immunomedics/
Twitter: https://twitter.com/ImmunomedicsInc
LinkedIn: https://www.linkedin.com/company/immunomedics/
